Chemistry:Xevinapant
From HandWiki
Xevinapant is an investigational new drug that is being evaluated to treat squamous cell cancer.[1] By acting as a SMAC mimetic, it functions as an inhibitor of several members of the IAP protein family (including XIAP, c-IAP1, and c-IAP2).[2]
References
- ↑ "Xevinapant - Merck & Co". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800030869.
- ↑ "Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck". Cancer Treatment Reviews 113. February 2023. doi:10.1016/j.ctrv.2022.102492. PMID 36640618.
 |  |
